csirt@kutim:~/threat-intel/cve/CVE-2026-3659

Katalog CVE

CVSS 6.4 · Medium EPSS 0,41%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'). Skor CVSS 3.1 6.4 (Medium) menurut wordfence.com.

Deskripsi (NVD)

The WP Circliful plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'id' shortcode attribute of the [circliful] shortcode and via multiple shortcode attributes of the [circliful_direct] shortcode in all versions up to and including 1.2. This is due to insufficient input sanitization and output escaping on user-supplied shortcode attributes. Specifically, in the circliful_shortcode() function, the 'id' attribute value is concatenated directly into an HTML id attribute (line 285) without any escaping, allowing an attacker to break out of the double-quoted attribute and inject arbitrary HTML event handlers. Similarly, the circliful_direct_shortcode() function (line 257) outputs all shortcode attributes directly into HTML data-* attributes without escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Rincian

Terbit di NVD
15 April 2026
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 3.1
6.4 (Medium), sumber wordfence.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,41% peluang dieksploitasi; lebih tinggi dari 33,1% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.